OS Therapies Incorporated
ASE: OSTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes OS Therapies Incorporated's price action across multiple timeframes using regression channels and statistical scoring.
Get OSTX Z-Score →About OS Therapies Incorporated
Healthcare
Biotechnology
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
📊 Fundamental Analysis
OS Therapies Incorporated demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $1.30, OSTX currently trades near the bottom of its 52-week range (11%), indicating potential value or weakness (Range: $1.15 - $2.57).
🏥 Financial Health
🔴
Profit Margin
Weak
Key Financials
Market Cap
$52.60M
Trailing P/E
--
Forward P/E
-4.59
Beta (5Y)
--
52W High
$2.57
52W Low
$1.15
Avg Volume
580K
Day High
Day Low